T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa

T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa

<p><strong>Objective(s):</strong> This study aimed to investigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T-cell responses 14 days after single-dose ChAdOx1 nCoV-19 (AZD1222) vaccination in...

Full description

Bibliographic Details
Main Authors:	McMahon, WC, Kwatra, G, Izu, A, Koen, AL, Greffrath, J, Fairlie, L, Patel, F, Mukendi, CK, Mbele, NJ, Lala, R, Burgers, WA, Nunes, MC, Cutland, CL, Gilbert, SC, Lambe, T, Pollard, AJ, Madhi, SA
Format:	Journal article
Language:	English
Published:	Wolters Kluwer 2023

Similar Items

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
by: Kaplonek, P, et al.
Published: (2023)

AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
by: Md. Altamash Ahmad, et al.
Published: (2023-03-01)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
by: Hillson, K, et al.
Published: (2021)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
by: Marchevsky, NG, et al.
Published: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
by: Natalie Gabrielle Marchevsky, et al.
Published: (2022-07-01)

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
by: Jonathan D. Ho, MBBS, DSc, DipDermpath, et al.
Published: (2022-07-01)

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
by: Neeltje van Doremalen, et al.
Published: (2022-08-01)

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients
by: Dharmendra S. Bhadauria, et al.
Published: (2022-10-01)

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
by: Karina Soboleva, et al.
Published: (2022-01-01)

REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
by: Maria da Penha Gomes Gouvea, et al.
Published: (2022-01-01)

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
by: David Benkeser, et al.
Published: (2023-03-01)

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
by: Janaína Jamile Ferreira Saraceno, et al.
Published: (2021-08-01)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
by: Watanabe, Y, et al.
Published: (2021)

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
by: Glenn A. Marsh, et al.
Published: (2021-05-01)

Native-like SARS-CoV‑2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
by: Yasunori Watanabe, et al.
Published: (2021-04-01)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
by: Clemens, SAC, et al.
Published: (2021)

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
by: Magdalena E. Sobieszczyk, et al.
Published: (2022-09-01)

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
by: Taylor S. Cohen, et al.
Published: (2022-05-01)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
by: Voysey, M, et al.
Published: (2020)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial
by: Ewer, K, et al.
Published: (2020)

Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle
by: Hyunji Choi, et al.
Published: (2021-12-01)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
by: Salma Al Bahrani, et al.
Published: (2021-09-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
by: Madhi, SA, et al.
Published: (2021)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
by: Voysey, M, et al.
Published: (2023)

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
by: Madhi, SA, et al.
Published: (2022)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
by: Evangelos Terpos, et al.
Published: (2021-07-01)

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)
by: Koen, AL, et al.
Published: (2023)

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
by: Swanson, PA, et al.
Published: (2021)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
by: Piyarat Limpawittayakul, et al.
Published: (2022-11-01)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
by: Voysey, M, et al.
Published: (2021)

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
by: Hamaluba, M, et al.
Published: (2023)

ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply
by: Madhi, SA, et al.
Published: (2021)

Profile of Humoral Immunity and B Cell Pool in Infection with the SARS-CoV-2 Prototype Strain and AZD1222 (ChAdOx nCoV-19) Vaccination
by: Débora Familiar-Macedo, et al.
Published: (2025-01-01)

Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study
by: Kathryn Shoemaker, et al.
Published: (2024-08-01)

Disseminated herpes zoster with varicella encephalitis and pneumonia following ChAdOx1 nCoV-19 (AZD1222) vaccine in an immunocompetent male-a case report
by: Ranitha Gopi, et al.
Published: (2024-06-01)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022-11-01)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
by: Kriangkrai Tawinprai, et al.
Published: (2023-01-01)

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population
by: Supamas Sirisreetreerux, et al.
Published: (2023-07-01)

Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases
by: Yen-Ju Chen, et al.
Published: (2022-08-01)

Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2
by: Sang Won Lee, et al.
Published: (2021-09-01)